Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies (NASDAQ:BRTX), a regenerative medicine company specializing in stem cell-based therapies, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024 in New York City.
CEO Lance Alstodt will represent the company at the conference, which will primarily consist of one-on-one investor meetings. Investors attending the conference who wish to meet with BioRestorative are advised to contact their ROTH MKM sales representative to arrange a meeting.
This participation provides an opportunity for BioRestorative to engage directly with investors and showcase its innovative work in stem cell-based therapies and products.
BioRestorative Therapies (NASDAQ:BRTX) announced that its Chief Scientist, Francisco Silva, will present at the 21st Annual IFATS Conference. The presentation will focus on the ThermoStem® platform's potential to deliver superior efficacy and tolerability compared to GLP-1 drugs for obesity treatment. Preclinical data showed significant reductions in weight, triglycerides, and blood glucose levels using BioRestorative's brown adipose-derived stem cells and 3D scaffold technology. The company believes its cell-based therapy may allow for lower dosing and avoid the lean muscle mass loss associated with GLP-1 drugs. BioRestorative is also developing a novel exosome-based biologic program targeting obesity and has begun discussions with a regenerative medicine company regarding potential licensing of its ThermoStem® intellectual property.
BioRestorative Therapies (NASDAQ:BRTX) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Improved financial performance: Loss from operations decreased 19% YoY to $2.5 million, while net loss improved 28% YoY to $4.0 million ($0.50 per share).
2. Strong cash position: $14.7 million in cash, cash equivalents, and marketable securities as of June 30, 2024, with no outstanding debt.
3. Progress in clinical programs: FDA clearance for protocol amendment in BRTX-100 Phase 2 study; development of novel exosome-based biologic program for obesity.
4. Commercial developments: Exclusive 5-year agreement with Cartessa Aesthetics for BioCosmeceuticals product supply, generating initial revenue in Q2 2024.
5. Intellectual property expansion: Notice of allowance for Japanese patent related to ThermoStem® platform.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, has announced it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, the company's management will host a conference call to review the financial results and provide a business update.
The conference call details are as follows:
- Date: Tuesday, August 13, 2024
- Time: 4:30 p.m. ET
- Domestic: 1-877-545-0523
- International: 1-973-528-0016
- Access Code: 151026
BioRestorative Therapies (NASDAQ:BRTX) announced that its Chief Scientist and VP of R&D, Francisco Silva, has been appointed Section Editor of the new Regenerative Medicine section in the Journal of Translational Medicine. This prestigious journal ranks among the top 3% worldwide with a 2021 impact factor of 8.440. Silva, who leads BRTX's cell-based therapeutics development, is currently the principal investigator for a Phase 2 study of BRTX-100 in treating chronic lumbar disc disease. He also pioneered the development of an artificial 3D brown adipose transplant using human brown adipose stem cells for the company's ThermoStem® program. Silva's appointment highlights BRTX's growing prominence in regenerative medicine research and development.
BioRestorative Therapies (NASDAQ:BRTX) has received a notice of allowance from the Japanese Patent Office for its ThermoStem® platform patent application. The patent covers a method of creating 3D brown adipose derived stem cell aggregates without differentiation medium. This complements their existing patent portfolio and supports potential licensing opportunities. Preclinical studies conducted with the University of Utah School of Medicine showed that ThermoStem® can reduce weight, triglyceride, and blood glucose levels in mice, mirroring the effects of GLP1 drugs. Substantive licensing discussions are ongoing with a commercial stage regenerative medicine company.
BioRestorative Therapies (NASDAQ: BRTX) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report on Form 10-Q for Q1 2024. The clinical-stage company focusing on stem cell therapies reported a significant year-over-year improvement in operating performance. For the quarter ending March 31, 2024, BRTX reported a loss from operations of $4.1 million, a 29% reduction from the $5.8 million loss in Q1 2023. The net loss for Q1 2024 was $2.2 million, or $0.33 per share, compared to $7.2 million, or $1.93 per share, in Q1 2023. Cash used in operating activities was $2.3 million, slightly less than the $2.4 million used in Q1 2023. BioRestorative ended the quarter with $16.4 million in cash, cash equivalents, and marketable securities.
BioRestorative Therapies (NASDAQ:BRTX) is in substantive discussions for a potential license agreement regarding its ThermoStem® metabolic disease program with an undisclosed regenerative medicine company.
ThermoStem® leverages brown adipose derived stem cells (BADSCs) to treat obesity and metabolic disorders.
Preclinical studies with the University of Utah demonstrated significant weight, triglyceride, and blood glucose reductions in mice.
The platform is supported by a comprehensive patent portfolio covering both U.S. and international markets.
While these discussions signal strong interest, no guarantees exist that a deal will be finalized.
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company specializing in stem cell-based therapies, announced that CEO Lance Alstodt will attend the Jefferies Global Healthcare Conference from June 5-6, 2024, at the Marriot Marquis in New York. The company will also hold one-on-one meetings with investors during the event.
BioRestorative Therapies (NASDAQ:BRTX) received a non-compliance notice from Nasdaq for not filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, on time. The notice was issued by Nasdaq's Listing Qualifications Department, highlighting a breach of Listing Rule 5250(c)(1), which mandates timely filing of all required periodic reports with the SEC.
The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days from the original filing due date to regain compliance, potentially extending the deadline to November 18, 2024. The company’s securities will continue to trade on Nasdaq under the symbol 'BRTX.' BioRestorative is making efforts to complete and file the Form 10-Q as soon as possible. This announcement follows Nasdaq's Listing Rule 5810(b), which requires immediate disclosure of such notifications.